Literature DB >> 26686035

Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism.

Rena Buckstein1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26686035     DOI： 10.1016/S2352-3026(15)00200-8

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN： 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  2 in total

1.  Exploring the Potential of Eltrombopag: Room for More?

Authors:  Francesco Tarantini; Cosimo Cumbo; Luisa Anelli; Antonella Zagaria; Maria Rosa Conserva; Immacolata Redavid; Giorgina Specchia; Pellegrino Musto; Francesco Albano
Journal:  Front Pharmacol       Date:  2022-05-23       Impact factor: 5.988

2.  Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.

Authors:  Michael Dickinson; Honar Cherif; Pierre Fenaux; Moshe Mittelman; Amit Verma; Maria Socorro O Portella; Paul Burgess; Pedro Marques Ramos; Jeea Choi; Uwe Platzbecker
Journal:  Blood       Date:  2018-10-10       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.